Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cyclacel Pharmaceuticals Inc    

 SummaryChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 2,00 M
EBIT 2017 -11,9 M
Net income 2017 -9,44 M
Debt 2017 -
Yield 2017 -
Sales 2018 2,00 M
EBIT 2018 -9,63 M
Net income 2018 -7,26 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 11,2x
Capi. / Sales2018 11,2x
Capitalization 22,4 M
More Financials
Company
Cyclacel Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel, mechanism-targeted drugs to treat cancer and other serious disorders.Its lead candidate, sapacitabine, oral nucleoside analogue prodrug that acts through a novel mechanism.It also develops... 
More about the company
Latest news on CYCLACEL PHARMACEUTICALS I
04/07 CYCLACEL PHARMACEUTICALS INC : Today's Research Reports on Biotech Stocks to Wat..
04/04 Cyclacel Presents Identification of Sensitive Target Indications and Synergis..
04/03 CYCLACEL PHARMACEUTICALS : `s Second-Generation CDK2/9 Inhibitor, CYC065, Elicit..
04/02 Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineo..
03/28 CYCLACEL PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, ..
03/28 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial ..
03/21 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2016 Financi..
03/13 CYCLACEL PHARMACEUTICALS, INC. (NASD : CYCC) Files An 8-K Other Events
03/13 CYCLACEL PHARMACEUTICALS, INC. : Other Events (form 8-K)
03/07 CYCLACEL PHARMACEUTICALS : CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a N..
More news
Sector news : Bio Therapeutic Drugs
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
04/18DJACTELION : J&J Lifts Forecast on Actelion Tie-Up--Update
04/18DJJOHNSON & JOHNSON : Lifts Forecast on Actelion Tie-Up
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug -- Up..
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
2016 Midday Gainers / Losers
2016 Midday Gainers / Losers
2016 Cyclacel's lead product candidates show encouraging results in early-stage st..
2016 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
2016 Some Ideas For The Next Celator
Advertisement
Chart CYCLACEL PHARMACEUTICALS I
Duration : Period :
Cyclacel Pharmaceuticals I Technical Analysis Chart | US23254L3069 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 7,00 $
Spread / Average Target 34%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Spiro Rombotis President, Chief Executive Officer & Director
David C. U'Prichard Chairman
Paul McBarron COO, CFO, Secretary, Director & Executive VP
David Glover Chief Scientist
John Michael Middlecott Banham Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CYCLACEL PHARMACEUTICA..7.17%22
AMGEN, INC.11.58%120 053
CELGENE CORPORATION6.39%95 807
GILEAD SCIENCES, INC.-7.49%86 604
REGENERON PHARMACEUTIC..0.83%39 455
ACTELION LTD26.98%30 323
More Results